查看文章

Background

Anti-TNFa therapies have improved response rates in inflammatory bowel disease. However primary loss of response is problematic.

Aim

Aim of this study was to explore relationship between infliximab (IFX) and adalimumab (ADA) trough and antibody levels with clinical response.

Method

This was a prospective, single centre study. Patients were recruited from July 2015-August 2016. Inclusion criteria were patients older than 17 years with IBD who started treatment with anti-TNFa drugs (infliximab/adalimumab) Patient demographics, clinical history were collected from electronic records. Clinical disease activity indexes were performed (Harvey-Bradshaw Index for Crohn's disease (CD), and partial Mayo scores for Ulcerative colitis (UC)). Clinical response defined as reduction in HBI≤ 3 or reduction in partial Mayo score≤ 4 and< 30% from baseline. Anti-TNFa trough and antibody levels were measured …